Moroxite has received Breakthrough Device Designation from the FDA for Xerafuse TOB, a bone graft extender designed to support spinal fusion while helping prevent bacterial colonization.
The designation is the company’s second under the FDA’s Breakthrough Devices Program, according to a Nov. 17 news release.
Xerafuse TOB is intended for patients at increased risk of infection undergoing sacrolumbar spinal fusion surgery. The resorbable material is designed to promote bone regeneration while releasing the antibiotic tobramycin to help prevent bacterial colonization after surgery.
Moroxite’s other product candidate, Xerafuse BMP, received breakthrough designation in 2025. It is being developed to stimulate bone formation and eliminate the need to harvest patients’ own bone during certain spinal fusion procedures.
The FDA’s breakthrough program provides opportunities for closer regulatory collaboration and prioritized review of future submissions. The designation does not constitute FDA clearance or approval.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
